Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PIPELINE ANALYSIS
5 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDERS TREATMENTS
6.1.2 EMERGING PERSONALIZED MEDICINE FOR LYSOSOMAL STORAGE DISORDERS
6.1.3 INCREASED GOVERNMENT FUNDING FOR RESEARCH INTO RARE DISEASE TREATMENTS
6.1.4 COLLABORATIONS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTIONS
6.2 RESTRAINTS
6.2.1 LACK OF AWARENESS AMONG HEALTHCARE PROFESSIONALS AND PATIENTS
6.2.2 PROLONGED DRUG APPROVAL PROCEDURES
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PIPELINE DRUGS
6.3.2 GROWING EMPHASIS ON EARLY DIAGNOSIS
6.3.3 ADVANCEMENTS IN GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS
6.4 CHALLENGES
6.4.1 SIGNIFICANT EXPENSES RELATED TO THE TREATMENT OF THE DISEASE
6.4.2 NARROW PATIENT BASE SUFFERING FROM LYSOSOMAL STORAGE DISORDERS
7 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER
7.1 OVERVIEW
7.2 GAUCHER DISEASE
7.2.1 TYPE 1
7.2.2 TYPE 3
7.2.3 TYPE 2
7.3 FABRY DISEASE
7.4 POMPE DISEASE
7.4.1 INFANTILE-ONSET POMPE
7.4.2 LATE-ONSET POMPE
7.5 MUCOPOLYSACCHARIDOSIS (MPS)
7.5.1 MPS I
7.5.2 MPS II
7.5.3 MPS IV
7.5.4 MPS VI
7.5.5 MPS III
7.6 NIEMANN-PICK DISEASE
7.6.1 TYPE C
7.6.2 TYPE B
7.6.3 TYPE A
7.7 KRABBE DISEASE
7.8 OTHERS
8 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS
8.1 OVERVIEW
8.2 IMIGLUCERASE
8.3 AGALSIDASE BETA
8.4 IDURSULFASE
8.5 ALGLUCOSIDASE ALPHA
8.6 VELAGLUCERASE
8.7 TALIGLUCERASE ALFA
8.8 LARONIDASE
8.9 AGALSIDASE ALPHA
8.1 GALSULFASE
8.11 AVALGLUCOSIDASE ALFA
8.12 OTHERS
9 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE
9.1 OVERVIEW
9.2 ENZYME REPLACEMENT THERAPY (ERT)
9.3 SUBSTRATE REDUCTION THERAPY (SRT)
9.4 CHAPERONE THERAPY
9.5 OTHERS
10 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER
10.1 OVERVIEW
10.2 MALE
10.3 FEMALE
11 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
11.4 GERIATRIC
12 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACIES
12.3 DRUGS STORES AND RETAIL PHARMACIES
12.4 ONLINE PHARMACIES
13 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INTRAVENOUS (IV)
13.3 SUBCUTANEOUS (SC)
13.4 ORAL
13.5 OTHERS
14 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 UNITED KINGDOM
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 RUSSIA
14.1.7 SWITZERLAND
14.1.8 TURKEY
14.1.9 BELGIUM
14.1.10 NETHERLANDS
14.1.11 DENMARK
14.1.12 SWEDEN
14.1.13 POLAND
14.1.14 NORWAY
14.1.15 FINLAND
14.1.16 REST OF EUROPE
15 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 SANOFI
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 BIOMARIN
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 AMICUS THERAPEUTIC, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 CHIESI FARMACEUTICI S.P.A.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 DENALI THERAPEUTICS
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PIPELINE PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 FORGE BIOLOGICS
17.8.1 COMPANY SNAPSHOT
17.8.2 PIPELINE PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 JCR PHARMACEUTICALS CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PINELINE PRODUCT PORTFOLIO
17.9.4 PRODUCT PORTFOLIO
17.9.5 RECENT DEVELOPMENT
17.1 ORCHARD THERAPEUTICS PLC
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 PROTALIX BIOTHERAPEUTICS
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PIPELINE PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 REGENXBIO INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PINELINE PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 SANGAMO THERAPEUTICS
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 SPUR THERAPEUTICS
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 ULTRAGENYX PHARMACEUTICAL INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 2 EUROPE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 3 EUROPE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 4 EUROPE FABRY DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 5 EUROPE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 6 EUROPE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 7 EUROPE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 8 EUROPE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9 EUROPE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 10 EUROPE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 11 EUROPE KRABBE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 12 EUROPE OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 13 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 14 EUROPE IMIGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 15 EUROPE AGALSIDASE BETA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 16 EUROPE IDURSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 17 EUROPE ALGLUCOSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 18 EUROPE VELAGLUCERASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 19 EUROPE TALIGLUCERASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 20 EUROPE LARONIDASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 21 EUROPE AGALSIDASE ALPHA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 22 EUROPE GALSULFASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 23 EUROPE AVALGLUCOSIDASE ALFA IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 24 EUROPE OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 25 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 26 EUROPE ENZYME REPLACEMENT THERAPY (ERT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 27 EUROPE SUBSTRATE REDUCTION THERAPY (SRT) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 28 EUROPE CHAPERONE THERAPY IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 29 EUROPE OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 30 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 31 EUROPE MALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 32 EUROPE FEMALE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 33 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 34 EUROPE PEDIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 35 EUROPE ADULT IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 36 EUROPE GERIATRIC IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 37 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 38 EUROPE HOSPITAL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 39 EUROPE DRUGS STORES AND RETAIL PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 40 EUROPE ONLINE PHARMACIES IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 41 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 42 EUROPE INTRAVENOUS (IV) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032(USD MILLION)
TABLE 43 EUROPE SUBCUTANEOUS (SC) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 44 EUROPE ORAL IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 45 EUROPE OTHERS IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 46 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 48 EUROPE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 49 EUROPE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 50 EUROPE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 51 EUROPE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 52 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 53 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 54 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 55 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 56 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 57 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 58 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 59 GERMANY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 60 GERMANY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 61 GERMANY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 62 GERMANY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 63 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 64 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 65 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 67 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 68 GERMANY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 69 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 70 UNITED KINGDOM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 71 UNITED KINGDOM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 72 UNITED KINGDOM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 73 UNITED KINGDOM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 74 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 75 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 76 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 77 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 78 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 79 UNITED KINGDOM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 81 FRANCE GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 82 FRANCE POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 83 FRANCE MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 84 FRANCE NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 85 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 86 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 87 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 89 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 90 FRANCE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 92 ITALY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 93 ITALY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 94 ITALY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 95 ITALY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 96 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 97 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 98 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 101 ITALY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 103 SPAIN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 104 SPAIN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 105 SPAIN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 106 SPAIN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 107 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 108 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 109 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 112 SPAIN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 114 RUSSIA GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 115 RUSSIA POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 116 RUSSIA MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 117 RUSSIA NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 118 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 119 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 120 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 123 RUSSIA LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 125 SWITZERLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 126 SWITZERLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127 SWITZERLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 128 SWITZERLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 129 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 130 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 131 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 134 SWITZERLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 136 TURKEY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 137 TURKEY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 138 TURKEY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 139 TURKEY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 140 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 141 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 142 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 145 TURKEY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 147 BELGIUM GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 148 BELGIUM POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 149 BELGIUM MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 150 BELGIUM NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 152 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 153 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 156 BELGIUM LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 158 NETHERLANDS GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 159 NETHERLANDS POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 160 NETHERLANDS MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 161 NETHERLANDS NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 163 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 164 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 166 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 167 NETHERLANDS LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 169 DENMARK GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 170 DENMARK POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 171 DENMARK MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 172 DENMARK NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 174 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 175 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 178 DENMARK LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 180 SWEDEN GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 181 SWEDEN POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 182 SWEDEN MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 183 SWEDEN NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 184 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 186 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 188 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 189 SWEDEN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 191 POLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 192 POLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 193 POLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 194 POLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 195 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 196 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 197 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 199 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 200 POLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 202 NORWAY GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 203 NORWAY POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 204 NORWAY MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 205 NORWAY NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 206 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 207 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 208 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 210 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 211 NORWAY LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
TABLE 213 FINLAND GAUCHER DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 214 FINLAND POMPE DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 215 FINLAND MUCOPOLYSACCHARIDOSIS (MPS) IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 216 FINLAND NIEMANN-PICK DISEASE IN LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 217 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 218 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 219 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 221 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY GENDER, 2018-2032 (USD MILLION)
TABLE 222 FINLAND LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223 REST OF EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER, 2018-2032 (USD MILLION)
List of Figure
FIGURE 1 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SEGMENTATION
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 SEVEN SEGMENTS COMPRISE THE EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET, BY TYPE OF DISORDER
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 BIOTECHNOLOGY ADVANCEMENTS FOR LYSOSOMAL STORAGE DISORDER TREATMENTS IS EXPECTED TO DRIVE THE EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN THE FORECAST PERIOD
FIGURE 14 GAUCHER DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET IN 2025 & 2032
FIGURE 15 PESTEL ANALYSIS
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET
FIGURE 17 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2024
FIGURE 18 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, 2025-2032 (USD MILLION)
FIGURE 19 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, CAGR (2025-2032)
FIGURE 20 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE OF DISORDER, LIFELINE CURVE
FIGURE 21 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2024
FIGURE 22 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, 2025-2032 (USD MILLION)
FIGURE 23 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, CAGR (2025-2032)
FIGURE 24 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 25 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2024
FIGURE 26 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, 2025-2032 (USD MILLION)
FIGURE 27 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 28 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 29 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2024
FIGURE 30 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, 2025-2032 (USD MILLION)
FIGURE 31 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 32 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2024
FIGURE 34 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, 2025-2032 (USD MILLION)
FIGURE 35 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 36 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 37 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 38 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
FIGURE 39 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 40 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 42 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
FIGURE 43 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 44 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 45 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: SNAPSHOT 2024
FIGURE 46 EUROPE LYSOSOMAL STORAGE DISORDER DRUGS MARKET: COMPANY SHARE 2024 (%)
